Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Mobile Infrastructure CorpNONE · Entity 90772 | Director | January 17, 2017 | January 20, 2017 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Mobile Infrastructure Corp
Report date January 17, 2017 · Filed January 20, 2017
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Series A Convertible Redeemable Preferred StockSEC Table I · non-derivative | Direct | 26.5 |
Reported balance
Holding disclosure · report date 2017-01-17 · row 1
Holding and transaction disclosures are not merged.
1 source rowRow 1 · Balance 26.5 |
| WarrantSEC Table II · derivative / convertible security | Direct | Not disclosed |
Reported balance
Holding disclosure · report date 2017-01-17 · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · Balance Not disclosed F1: The Warrants may be exercised after the 90th day following the occurrence of a Listing Event, at an exercise price, per share, equal to 110% of the volume weighted average closing price during the 20 trading days ending on the 90th day after the occurrence of such Listing Event; however, in no event shall the exercise price of the Warrants be less than $25 per share. F2: The Warrants will expire five years from the 90th day after the occurrence of a Listing Event. In addition, if a Listing Event does not occur on or prior to the fifth anniversary of the final Closing date of this Offering, then all outstanding Warrants will expire automatically on such anniversary date without being exercisable by the holders thereof. |
Filing footnotes · ownership attribution and instrument terms
F1: The Warrants may be exercised after the 90th day following the occurrence of a Listing Event, at an exercise price, per share, equal to 110% of the volume weighted average closing price during the 20 trading days ending on the 90th day after the occurrence of such Listing Event; however, in no event shall the exercise price of the Warrants be less than $25 per share.
F2: The Warrants will expire five years from the 90th day after the occurrence of a Listing Event. In addition, if a Listing Event does not occur on or prior to the fifth anniversary of the final Closing date of this Offering, then all outstanding Warrants will expire automatically on such anniversary date without being exercisable by the holders thereof.
Past disclosures · reporting ended (1)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
Ernexa Therapeutics Inc.
Report date March 24, 2021 · Filed March 27, 2021
Section 16 reporting ended · disclosed 2021-03-27. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 128,520 |
Reported balance
After 2021-03-24 transaction · row 1
1 source rowRow 1 · 2021-03-24 · Tax withholding · Disposed 9,944 · Balance 128,520 F1: These shares were withheld by the issuer to satisfy statutory tax withholding requirements on vesting of restricted stock units that occurred in connection with the closing of the merger (the "Merger") contemplated by the Agreement and Plan of Merger and Reorganization (the "Merger Agreement") by and among NTN Buzztime Inc., BIT Merger Sub, Inc. and Brooklyn Immunotherapeutics LLC. The number of shares withheld was determinable on March 24, 2021. No shares were sold in connection with this transaction. None of the share amounts in this Form 4 reflect the 2 for 1 reverse stock split implemented by the issuer on March 25, 2021 in connection with the Merger. |
| Common StockSEC Table I · non-derivative | IndirectSee footnote | 2,100 |
Reported balance
Holding disclosure · report date 2021-03-24 · row 2
Holding and transaction disclosures are not merged.
1 source rowRow 2 · Balance 2,100 F2: As custodian of Child 1. |
| Common StockSEC Table I · non-derivative | IndirectSee footnote | 2,100 |
Reported balance
Holding disclosure · report date 2021-03-24 · row 3
Holding and transaction disclosures are not merged.
1 source rowRow 3 · Balance 2,100 F3: As custodian of Child 2. |
Filing footnotes · ownership attribution and instrument terms
F1: These shares were withheld by the issuer to satisfy statutory tax withholding requirements on vesting of restricted stock units that occurred in connection with the closing of the merger (the "Merger") contemplated by the Agreement and Plan of Merger and Reorganization (the "Merger Agreement") by and among NTN Buzztime Inc., BIT Merger Sub, Inc. and Brooklyn Immunotherapeutics LLC. The number of shares withheld was determinable on March 24, 2021. No shares were sold in connection with this transaction. None of the share amounts in this Form 4 reflect the 2 for 1 reverse stock split implemented by the issuer on March 25, 2021 in connection with the Merger.
F2: As custodian of Child 1.
F3: As custodian of Child 2.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| November 04, 2016 Filed Nov 8, 2016 00:30 UTC | Ernexa Therapeutics Inc. NTN · Entity 8278 | GrantCommon Stock | 26,000 | $6.64 | $172,640.00 |
DisclosureSEC source: 0001493152-16-014599 · form4.xml · nonDerivative · entry 1 Wolff Allen · CIK 0001628529 · CFO and EVP 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 27,910 Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.